Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection

被引:49
|
作者
Yönem, A
Çakir, B
Güler, S
Azal, Ö
Çorakçi, A
机构
[1] Gulhane Sch Med, Dept Endocrinol, Ankara, Turkey
[2] Ankara Educ & Res Hosp, Dept Endocrinol & Metab, Ankara, Turkey
来源
DIABETES OBESITY & METABOLISM | 2001年 / 3卷 / 05期
关键词
granulocyte-colony stimulating factor; diabetes mellitus; diabetic foot infection; respiratory burst; phagocytosis; polymorphonuclear leucocytes;
D O I
10.1046/j.1463-1326.2001.00142.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Foot infections and the subsequent amputation of a lower extremity are the most common cause of hospitalization among patients with diabetes mellitus. Although there are several reasons for susceptibility to infection in diabetic patients, white blood cell dysfunction is considered to be an important cause for this tendency. Granulocyte-colony stimulating factor (G-CSF) increases the release of neutrophils from the bone marrow and improves neutrophil functions. Based on this knowledge, the aim of the present study was to investigate the effects of addition of G-CSF to the treatment of foot infections in diabetic patients. Methods: Thirty diabetic patients with foot infection were included in the study. Fifteen of the patients received standard treatment consisting of local wound care and antibiotics (standard goup), and the other 15 patients received G-CSF besides standard treatment (G-CSF group). The objectives of this study were to determine the time to resolution of infection, time to hospital discharge, need for surgical intervention, and the effects of G-CSF on phagocytosis and respiratory burst of neutrophils. Results: Treatment with G-CSF led to significantly higher neutrophil counts on the 5th and loth days, and at the end of treatment in the G-CSF treated group compared to the standard group. Respiratory burst of neutrophils increased significantly in both the G-CSF group (from 1.6 +/-0.3 to 2.3 +/-0.5. p=0.001) and the standard group (from 2.0 +/-0.4 to 2.3 +/-0.4, p=0.02) with treatment. But, while phagocytosis of neutrophils increased significantly in the G-CSF group (from 70.4 +/-2.0 to 74.5 +/-1.9, p=0.004), it did not change significantly in the standard group (from 68.1 +/-0.2 to 69.4 +/-1.9, p=0.3) with treatment. Duration of hospitalization (26.9 +/-2.0 vs. 28.3 days, p<0.05), duration of parenteral antibiotic administration (22.9<plus/minus>2.0 vs. 23.3 +/-1.9 days, p<0.05), time to resolution of infection (23.6<plus/minus>1.8 vs. 22.3 +/-1.7 days, p<0.05), and need for amputation (13.3% vs. 20%, p>0.05) were similar between the G-CSF and the standard groups. Conclusions: Although G-CSF improves neutrophil function as well as increasing the absolute numbers, this improvement is not associated with shortening of duration of antibiotic administration, duration of hospital stay or need for amputation in diabetic foot infection.
引用
收藏
页码:332 / 337
页数:6
相关论文
共 50 条
  • [11] Comparison of granulocyte-colony, stimulating factor and granulocyte macrophage-colony stimulating factor in the treatment of chemotherapy extravasation ulcers
    Ulutin, HC
    Güden, M
    Dede, M
    Pak, Y
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2000, 21 (06) : 613 - 615
  • [12] Granulocyte-colony stimulating factor for the treatment of Parkinson's disease
    Frank, T.
    Meuer, K.
    Klinker, F.
    Liebetanz, D.
    Schulz, J. B.
    Baehr, M.
    Schneider, A.
    Weishaupt, J. H.
    JOURNAL OF NEURAL TRANSMISSION, 2009, 116 (02) : 249 - 250
  • [13] Granulocyte-colony Stimulating Factor Treatment of Chronic Myocardial Infarction
    Louzada, Ruy A. N.
    Oliveira, Patricia F.
    Cavalcanti-de-Albuquerque, Joao Paulo A.
    Cunha-Carvalho, Leandro
    Baldanza, Marcelo R.
    Kasai-Brunswick, Tais H.
    Goldenberg, Regina C. S.
    Campos-de-Carvalho, Antonio C.
    Werneck-de-Castro, Joao P. S.
    CARDIOVASCULAR DRUGS AND THERAPY, 2010, 24 (02) : 121 - 130
  • [14] Granulocyte-colony Stimulating Factor Treatment of Chronic Myocardial Infarction
    Ruy A. N. Louzada
    Patricia F. Oliveira
    Joao Paulo A. Cavalcanti-de-Albuquerque
    Leandro Cunha-Carvalho
    Marcelo R. Baldanza
    Taís H. Kasai-Brunswick
    Regina C. S. Goldenberg
    Antonio C. Campos-de-Carvalho
    Joao P. S. Werneck-de-Castro
    Cardiovascular Drugs and Therapy, 2010, 24 : 121 - 130
  • [15] The clinical use of granulocyte-colony stimulating factor
    Shah, Jagruti
    Welsh, Sarah J.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2014, 75 (02) : C29 - C32
  • [16] A novel neuroprotectant granulocyte-colony stimulating factor
    Solaroglu, I
    Cahill, J
    Jadhav, V
    Zhang, JH
    STROKE, 2006, 37 (04) : 1123 - 1128
  • [17] Clinical applications of granulocyte-colony stimulating factor
    Sung, Lillian
    Dror, Yigal
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 : 1988 - 2002
  • [18] Neuroprotective effect of granulocyte-colony stimulating factor
    Solaroglu, Ihsan
    Jadhav, Vikram
    Zhang, John H.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 : 712 - 724
  • [19] Granulocyte-colony stimulating factor or granulocyte-colony stimulating factor associated to stem cell intracoronary infusion effects in non ischemic refractory heart failure
    Bocchi, Edimar Alcides
    Bacal, Fernando
    Guimaraes, Guilherme
    Mendroni, Alfredo
    Mocelin, Amilcar
    Filho, Antonio Esteves
    da Cruz, Fatima das Dores
    Resende, Marcos Coimbra
    Chamone, Dalton
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 138 (01) : 94 - 97
  • [20] Granulocyte-colony stimulating factor for the treatment of ritodrine-induced neutropenia
    Kikkawa, Masashi
    Matsubara, Shigeki
    Takatoku, Masaaki
    Kuwata, Tomoyuki
    Ohkuchi, Akihide
    Izumi, Akio
    Watanabe, Takashi
    Suzuki, Mitsuaki
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2008, 34 (02) : 286 - 290